Document is current
Any future updates will be listed below
-
Authors
Chandrasekaran, Abarajithan
Malek-Ahmadi, Michael
Decourt, Boris
Sabbagh, Marwan N.
- License Information
-
More Information
Article History
Received: 5 August 2025
Accepted: 21 November 2025
First Online: 25 December 2025
Declarations
:
: Abarajithan Chandrasekaran has nothing to disclose. Marwan N. Sabbagh discloses that he consults for Alzheon, Athira, Biogen, Roche-Genentech, Synaptogenix, Novo Nordisk, Signant Health, Prothena, Eisai, GSK, Abbvie, Lilly, and Neurotherapia. Marwan N. Sabbagh is an Editor-in-Chief of Neurology and Therapy . Marwan N. Sabbagh was not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions. Boris Decourt is a consultant for Lighthouse Pharmaceuticals. Michael Malek-Ahmadi discloses that he consults for the Biomedical Research Alliance of New York
: This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.
